---
title: "TXD: Has repurchased 20.0252 million shares with a total fund amount of 278 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/245428388.md"
description: "TXD announced that as of June 20, 2025, the company has repurchased a total of 20.0252 million shares through a special repurchase account via centralized bidding, accounting for 6.11% of the company's existing total share capital, with a highest transaction price of 15.08 yuan/share, a lowest transaction price of 12.85 yuan/share, and a total transaction amount of 278 million yuan. This repurchase implementation complies with the requirements of relevant laws and regulations as well as the company's established repurchase plan"
datetime: "2025-06-20T11:04:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/245428388.md)
  - [en](https://longbridge.com/en/news/245428388.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/245428388.md)
generator: "portal-rs"
---

# TXD: Has repurchased 20.0252 million shares with a total fund amount of 278 million yuan

TXD announced that as of June 20, 2025, the company has repurchased a total of 20.0252 million shares through a dedicated repurchase account via centralized bidding, accounting for 6.11% of the company's existing total share capital, with a highest transaction price of 15.08 yuan/share and a lowest transaction price of 12.85 yuan/share, totaling 278 million yuan. This repurchase implementation complies with the requirements of relevant laws and regulations as well as the company's established repurchase plan

### Related Stocks

- [002845.CN](https://longbridge.com/en/quote/002845.CN.md)

## Related News & Research

- [Apollo Atomics wants to make nuclear power cheaper by shrinking an overlooked part](https://longbridge.com/en/news/296502139.md)
- [Pinnacle West Capital Stock: Analyst Estimates & Ratings](https://longbridge.com/en/news/296614145.md)
- [REG - Origin Enterprises - Holding(s) in Company](https://longbridge.com/en/news/296240027.md)
- [REG - Distil PLC - Holding(s) in Company](https://longbridge.com/en/news/296222089.md)
- [Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data](https://longbridge.com/en/news/296388332.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**